Vijay Suppiah

Dr Vijay Suppiah

Senior Lecturer, Pharmacy

School of Pharmacy and Biomedical Science

College of Health

Available For Media Comment.

Dr Vijay Suppiah joined Clinical and Health Sciences in June 2011. Prior to his appointment at UniSA, Dr Suppiah was a postdoctoral scientist at the University of Sydney (Western Medical School) where he was leading a pharmacogenomics project in hepatitis C. His academic journey includes Pharmacy education at the National University of Singapore and doctoral research in immunogenetics at the Queen’s University of Belfast (Northern Ireland).
Dr Suppiah coordinates two third year courses, Dosage Form Design 3 (PHAR3024) and Pharmacotherapeutics Theory 2 (PHAR3022) in the Pharmacy and Pharmaceutical Science programs. Both courses teach professional skills and knowledge to aspiring practitioners of pharmacy and pharmaceutical science.
Dr Suppiah’s research interest of pharmacogenomics in multimorbidity strongly aligns with the Australian Centre for Precision Health (ACPreH) at UniSA. His research projects are based on patients' genetic make-up in informing medication choices mainly in cancer and mental health. Additionally, he is also interested in the use of and long term effects of psychotropic medications across the lifespan.
Dr Suppiah shares his passion for research with undergrad and postgrad students both within UniSA and externally. He continues to supervise innovative Frontiers projects which have resulted in several joint publications with students. As a primary supervisor, he has supervised several higher degree students to completion. His team provides a supportive and nurturing environment to cultivate independent thinkers. 

My vision is for a future in which medications for all ailments are prescribed based on a person's genetic make-up. A person's genetic architecture not only determines their susceptibility to diseases but also the way they are likely to respond to pharmacotherapy. The future of medicine lies in understanding and appreciating that everyone should be treated as unique individuals, specifically when it comes to medication and dose selection. Some medical specialities do this very well while it is still developing in other areas. I believe that psychopharmacotherapy would greatly benefit from this approach to the selection of medication and dose. 

Pharmacogenomics in multi-morbidity

A person's genetic make-up can influence their treatment outcomes (response and adverse drug reactions). With the advancement of genetic technologies and the reduction in costs for genetic projects, it is fast becoming a reality to do these projects within a reasonable time frame and budget. The implications of these projects will revolutionise the way doctors prescribe drugs for their patients.

Mental health and use of psychotropic medications

Community pharmacists are one of the most trusted primary healthcare professionals in Australia. Research projects under this stream are aimed at increasing the reach of community pharmacists to enhance the mental health and wellbeing of their communities. Additionally, projects are also aimed at investigating the long-term effects of psychotropic medications. 

I would like to share my vision with students and colleagues in Australia as well as internationally. I collaborate widely with academics and industrial partners who are inspired to lead change for a better future world. 

Year Citation
2025 Janetzki, J. L., Chai, W. C., Bui, T. N. T., Sim, T. F., & Suppiah, V. (2025). Impact of medicine shortages on Australian pharmacists' professional practice and patient care: a nationwide survey. Journal of Pharmacy Practice and Research, 55(2), 146-153.
DOI Scopus2 WoS3
2025 Moore, J., Singh, I., Au, R. T., Gabb, G., Eng-Frost, J., Hotham, E., . . . Suppiah, V. (2025). Psychotropic Polypharmacy and QT Prolonging Medications in Hospitalized Patients. Pharmacology Research and Perspectives, 13(3), 7 pages.
DOI Scopus1 WoS1 Europe PMC1
2025 Kalisch Ellett, L. M., Janetzki, J. L., Suppiah, V., Chai, W., Staff, K., Amato, D., . . . Ward, M. B. (2025). Quantifying the non-remunerated services provided by pharmacists in community pharmacies: a direct observational study. International Journal of Pharmacy Practice, online, 1-8.
DOI
2025 Ayeno, H. D., Atee, M., Kassie, G. M., Suppiah, V., Widagdo, I., & Nguyen, T. A. (2025). Psychotropic medications versus non-pharmacologic approaches for managing behavioural and psychological symptoms in Australian aged care residents with dementia: general practitioners’ and physicians’ perspectives. Therapeutic Advances in Psychopharmacology, 15(20451253251387908), 15 pages.
DOI
2025 Thiruchelvam, T., Lim, C. X., Munro, C., Chan, V., Jayasuria, G., Coulthard, K. P., . . . Suppiah, V. (2025). Adverse Events and Drug Interactions Associated with Elexacaftor/Tezacaftor/Ivacaftor Treatment: A Descriptive Study Across Australian, Canadian, and American Adverse Event Databases. Life, 15(8), 10 pages.
DOI
2025 Katranski, J., Liang, S., Morris, D., Suppiah, V., & Lim, C. X. (2025). Psychiatric adverse events linked to glucagon-like peptide 1 analogues: a disproportionality analysis in American, Canadian and Australian adverse event databases. International Journal of Clinical Pharmacy, 47(6), 1739-1747.
DOI Scopus1 WoS1 Europe PMC1
2025 Bui, T. N. T., Au, R. T., Janetzki, J. L., McMillan, S. S., Hotham, E., & Suppiah, V. (2025). Metabolic monitoring for adults living with a serious mental illness on a second-generation antipsychotic agent: a scoping review. Administration and Policy in Mental Health and Mental Health Services Research, 52(2), 289-317.
DOI Scopus2 WoS2 Europe PMC1
2024 Cooper, M. B., McMillan, S., Dunkley, K., Kelly, F., McDermott, B., Hotham, E., & Suppiah, V. (2024). Peer support as a potential tool to promote pharmacists’ wellbeing. Journal of the American Pharmacists Association, 64(4), 5 pages.
DOI
2024 Papachristos, A., Cusato, J., Nair, S., Maggo, S., & Suppiah, V. (2024). Editorial: Utilization of pharmacogenomics in clinical practice. FRONTIERS IN GENETICS, 15(1470698), 3 pages.
DOI
2024 Singleton, J., Stevens, J. E., Truong, R., McColloch, A., Ara, E., Cooper, M. B., . . . Suppiah, V. (2024). Consumer knowledge of mental health conditions, awareness of mental health support services, and perception of community pharmacists' role in mental health promotion. International Journal of Pharmacy Practice, 32(2), 170-179.
DOI Scopus2 WoS2 Europe PMC2
2024 Au, R. T., Hotham, E., Esterman, A., Shakib, S., & Suppiah, V. (2024). Changes in sedative burden at discharge in hospitalised patients experiencing psychotropic polypharmacy. Schizophrenia Research, 266, 90-91.
DOI Scopus1 WoS1 Europe PMC1
2024 Stacey, D., Suppiah, V., Benyamin, B., Lee, S. H., & Hyppönen, E. (2024). In-silico functional analyses identify TMPRSS15-mediated intestinal absorption of lithium as a modulator of lithium response in bipolar disorder. Journal of Affective Disorders, 358, 416-421.
DOI Scopus2 WoS2 Europe PMC2
2023 Yow, H. -Y., Hamzah, S., Suppiah, V., & Abdul Rahim, N. (2023). Pharmacogenomics of response to statin treatment and susceptibility to statin-induced adverse drug reactions in Asians: a scoping review. ASIAN BIOMEDICINE, 17(3), 95-114.
DOI Scopus5 WoS5 Europe PMC4
2023 Mulugeta, A., Suppiah, V., & Hyppönen, E. (2023). Corrigendum to “Schizophrenia and co-morbidity risk: Evidence from a data driven phenomewide association study” [J. Psychiatr. Res. 162 (2023) 1–10, (S0022395623001747), (10.1016/j.jpsychires.2023.04.010)]. Journal of Psychiatric Research, 165, 344.
DOI
2023 Bremmell, K. E., Barnes, T. J., Hughes, B. P., Birbeck, D. J., Johnson, J., & Suppiah, V. (2023). Design and implementation of a program wide pharmaceutical compounding curriculum using the scaffold learning approach. CURRENTS IN PHARMACY TEACHING AND LEARNING, 15(2), 178-185.
DOI Scopus1 WoS1
2023 Cooper, M., McMillan, S., Dunkley, K., Hotham, E., Buccheri, J., McDermott, B., . . . Suppiah, V. (2023). In shortage: the impact on pharmacy. Australian Journal of Pharmacy, online.
2023 Cooper, M., McMillan, S., Hotham, E., Dunkley, K., Buccheri, J., Kelly, F., . . . Suppiah, V. (2023). Rats in the ranks: pharmacy and Covid testing examined. Australian Journal of Pharmacy, online.
2023 Janetzki, J., Chai, W., Bui, T., Sim, F., & Suppiah, V. (2023). The impact of medication shortages.. Australian Journal of Pharmacy, online.
2023 Cooper, M., McMillan, S., Dunkley, K., Hotham, E., Buccheri, J., McDermott, B., . . . Suppiah, V. (2023). Fake news and aggression in the pandemic.. Australian Journal of Pharmacy., online.
2023 Cooper, M., McMillan, S., Hotham, E., Dunkley, K., Buccheri, J., McDermott, B., . . . Suppiah, V. (2023). Covid and medication: how research emerged. Australian Journal of Pharmacy, online.
2023 Cooper, M., McMillan, S., Hotham, E., Dunkley, K., Buccheri, J., Kelly, F., . . . Suppiah, V. (2023). The impact of Covid-19 on pharmacy legislation and innovative changes.. Australian Journal of Pharmacy, online.
2023 Cooper, M., Hotham, E., McMillan, S., Buccheri, J., Kelly, F., McDermott, B., & Suppiah, V. (2023). The effect of COVID-19 on pharmacists' role as immunisers. Australian Journal of Pharmacy, online.
2023 Cooper, M., McMillan, S., Dunkley, K., Hotham, E., Buccheri, J., McDermott, B., . . . Suppiah, V. (2023). Risky business: How covid hit the bottom line.. Australian Journal of Pharmacy, online.
2023 Taing, M. -W., Choong, J., Suppiah, V., El-Den, S., Park, J. S., Mccullough, M., & Teoh, L. (2023). A Cross-Sectional Survey Exploring Australian Pharmacists' and Students' Management of Common Oral Mucosal Diseases. PHARMACY, 11(5), 13 pages.
DOI WoS2 Europe PMC3
2023 Au, R. T., Hotham, E., & Suppiah, V. (2023). Guidelines and treatment for illicit drug related presentations in emergency departments: A scoping review. Australasian Psychiatry, 31(5), 625-634.
DOI Scopus3 WoS2 Europe PMC3
2023 Bui, T. N. T., Janetzki, J. L., Chai, W. C., & Suppiah, V. (2023). Exploring consumers' perspective of community pharmacists delivering COVID-19 vaccinations: an Australian pilot study. International Journal of Pharmacy Practice, 31(3), 337-340.
DOI Scopus3 WoS3 Europe PMC2
2023 Mulugeta, A., Suppiah, V., & Hyppönen, E. (2023). Schizophrenia and co-morbidity risk: Evidence from a data driven phenomewide association study. Journal of Psychiatric Research, 162, 1-10.
DOI Scopus10 WoS8 Europe PMC8
2023 Chapman-Goetz, J., Packham, N., Yu, K., Gabb, G., Potts, C., Prosser, A., . . . Suppiah, V. (2023). NPS MedicineWise application in supporting medication adherence in chronic heart failure: an acceptability and feasibility pilot study. Frontiers in Digital Health, 5(1274355), 10 pages.
DOI WoS1 Europe PMC1
2022 Bui, T. N. T., Hotham, E., Kelly, F., & Suppiah, V. (2022). Feasibility of a pharmacist-led physical health monitoring for patients on antipsychotic medications: protocol for a longitudinal study. BMJ Open, 12(6, article no. e059573), 1-6.
DOI
2022 Bui, T. N. T., Hotham, E., Loughhead, M., McMillan, S. S., Procter, N., Poole, K., & Suppiah, V. (2022). Exploring mental health clients' current medication knowledge, beliefs and experience with healthcare providers in the community in South Australia. Health and Social Care in the Community, 30(6), e5968-e5978.
DOI Scopus5 WoS5 Europe PMC6
2022 Bui, T. N. T., Hotham, E., Rose, L., & Suppiah, V. (2022). COVID-19 and mental illness: perceptions of the pandemic and adherence to pandemic public health measures. Australasian Psychiatry, 30(6), 774-776.
DOI
2022 Satkunananthan, S. E., Suppiah, V., Toh, G. T., & Yow, H. Y. (2022). Pharmacogenomics of cancer pain treatment outcomes in Asian populations: a review. Journal of Personalized Medicine, 12(11), 1-18.
DOI Scopus4 WoS4 Europe PMC2
2022 Bandiera, C., Skrabal Ross, X., Cardoso, E., Wagner, D., Csajka, C., Olver, I., . . . Schneider, M. (2022). Interventions to support adherence to oral anticancer therapies: research challenges, lessons learned, and strategies to overcome them from Australia and Switzerland. Supportive Care in Cancer, 30(5), 3655-3659.
DOI Scopus1 WoS1 Europe PMC1
2022 Skrabal, R. X., Gunn, K. M., Suppiah, V., Patterson, P., Boyle, T., Carrington, C., . . . Olver, I. (2022). A smartphone program to support adherence to oral chemotherapy in people with cancer: proof-of-concept trial. Asia-Pacific Journal of Clinical Oncology, 18(5), e378-e387.
DOI Scopus3 WoS3 Europe PMC3
2022 Chapman Goetz, J., Packham, N., Gabb, G., Potts, C., Yu, K., Prosser, A., . . . Suppiah, V. (2022). Acceptability and feasibility of the NPS MedicineWise mobile phone application in supporting medication adherence in patients with chronic heart failure: protocol for a pilot study. PLoS ONE, 17(2, article no. e0263284), 1-13.
DOI Scopus2 WoS2 Europe PMC2
2022 Roberts, G., Baker, M., Leiblich, H., Paulose, M., Pegoli, M., Panagopoulos, L., . . . Suppiah, V. (2022). Hospitalisation and associated costs of gastrointestinal bleeding from primary prevention aspirin use in South Australia: a retrospective case series analysis. Internal Medicine Journal, 52(2), 318-321.
DOI Scopus4 WoS4 Europe PMC3
2022 Yow, H. Y., Satkunananthan, S. E., Suppiah, V., & Toh, G. T. (2022). Towards precision medicine for cancer pain treatment in Asian populations.. Pharma Focus Asia, (51), 36-39.
2021 Suppiah, V., Kelly, F., Watt, O., Wheeler, A. J., Hotham, E., & McMillan, S. (2021). Mental well-being promotion by Australian community pharmacists: what's happening and what needs to be done?. Journal of Pharmaceutical Health Services Research, 12(4), 587-590.
DOI Scopus1 WoS1
2021 Bui, T. N. T., Stahl, H. J., Kaplan, J., Hotham, E., Loffler, H., Corlis, M., & Suppiah, V. (2021). Administration of as-needed psychotropic medications in aged care: decision matrix employed by nursing staff. Journal of the American Medical Directors Association, 22(3), 721-723.
DOI
2021 McCallum, B. A., Dunkley, K., Hotham, E., & Suppiah, V. (2021). Bushfires, COVID-19 and Australian community pharmacists: ongoing impact on mental health and wellbeing. International Journal of Pharmacy Practice, 29(2), 186-188.
DOI Scopus9 WoS11 Europe PMC8
2021 Nisselle, A., Janinski, M., Martyn, M., McClaren, B., Kaunein, N., Barlow-Stewart, K., . . . Gaff, C. (2021). Ensuring best practice in genomics education and evaluation: reporting item standards for education and its evaluation in genomics (RISE2 Genomics). Genetics in Medicine, 23(7), 1356-1365.
DOI Scopus47 WoS37 Europe PMC33
2021 Gebremichael, L. G., Suppiah, V., Wiese, M. D., Mackenzie, L., Phillips, C., Williams, D. B., & Roberts, M. S. (2021). Efficacy and safety of statins in ethnic differences: a lesson for application in Indigenous Australian patient care. Pharmacogenomics, 22(9), 553-571.
DOI Scopus1
2020 Johnson, J., Aburas, D., Adaire, P., Ivanka, K., & Suppiah, V. (2020). Exploring prescribing patterns and handover to primary care for geriatric patients: results from a preliminary study. Pain medicine, 21(10), 2616-2619.
DOI
2020 Skrabal Ross, X., Gunn, K. M., Suppiah, V., Patterson, P., & Olver, I. (2020). A review of factors influencing non-adherence to oral antineoplastic drugs. Support Care Cancer, 28(9), 4043-4050.
DOI Scopus34 WoS31 Europe PMC22
2020 Bony, H., Lloyd, R. A., Hotham, E. D., Corre, L. J., Corlis, M. E., Loffler, H. A., . . . Suppiah, V. (2020). Differences in the prescribing of potentially inappropriate medicines in older Australians: comparison of community dwelling and residential aged care residents. Scientific Reports, 10(1, article no. 10170), 1-8.
DOI Scopus10 WoS9 Europe PMC9
2020 Johnson, J., Aburas, D., Prosser, A., Koeper, I., & Suppiah, V. (2020). Corrigendum to: Exploring Prescribing Patterns and Handover to Primary Care for Geriatric Patients: Results from a Preliminary Study.. Pain medicine (Malden, Mass.), 22(1), 236.
DOI
2018 Hotham, E. D., Lloyd, R. A., Petito, E. S., & Suppiah, V. (2018). Medication administration issues in residential aged care - four cases. Journal of clinical gerontology & geriatrics, 9(4), 156-159.
DOI
2018 Corre, L. J., Hotham, E., Tsimbinos, J., Todd, I., Scarlett, G., & Suppiah, V. (2018). Assessment of patient understanding of their medicines: interviews with community dwelling older Australians. International journal of pharmacy practice, 26(6), 568-572.
DOI Scopus3 WoS1 Europe PMC2
2018 Suppiah, V., Lim, C. X., & Hotham, E. (2018). Community pharmacists and their role in pharmacogenomics testing: an Australian perspective drawing on international evidence. Australian journal of primary health, 24(6), 441-447.
DOI Scopus5 WoS6 Europe PMC6
2017 Lloyd, R. A., Hotham, E. D., Hall, C., Williams, M., & Suppiah, V. (2017). Pharmacogenomics and patient treatment parameters to opioid treatment in chronic pain: a focus on morphine, oxycodone, tramadol, and fentanyl. Pain medicine, 18(12), 2369-2387.
DOI Scopus21 WoS20 Europe PMC17
2017 Mahurkar, S., Moldovan, M., Suppiah, V., Sorosina, M., Clarelli, F., Liberatore, G., . . . King, C. (2017). Response to interferon-beta treatment in multiple sclerosis patients: A genome-wide association study. Pharmacogenomics Journal, 17(4), 312-318.
DOI Scopus26 WoS24 Europe PMC24
2017 Read, S. A., O'Connor, K. S., Suppiah, V., Ahlenstiel, C. L. E., Obeid, S., Cook, K. M., . . . Ahlenstiel, G. (2017). Zinc is a potent and specific inhibitor of IFN-λ3 signalling. Nature Communications, 8(15245), 15245-1-15245-15.
DOI Scopus53 WoS51 Europe PMC42
2015 Rueger, S., Bochud, P. Y., Dufour, J. F., Mullhaupt, B., Suppiah, V., & Negro, F. (2015). Impact of common risk factors of fibrosis progression in chronic hepatitis C. Gut, 64(10), 1605-1615.
DOI Scopus81 WoS74 Europe PMC61
2015 Eslam, M., Hashem, A. M., Leung, R., Romero-Gomez, M., Berg, T., Dore, G. J., . . . Santaro, R. (2015). Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nature Communications, 6(1), 6422-1-6422-10.
DOI Scopus163 WoS158 Europe PMC134
2014 Yip, T., O'Doherty, C., Tan, N., Dibbens, L., & Suppiah, V. (2014). SCN1A variations and response to multiple antiepileptic drugs. Pharmacogenomics Journal, 14(4), 385-389.
DOI Scopus24 WoS22 Europe PMC22
2014 Hopkins, A., O'Doherty, C., Foster, D., Suppiah, V., Upton, R., Spargo, L., . . . Wiese, M. (2014). The rheumatoid arthritis susceptibility polymorphism PTPN22 C1858T is not associated with leflunomide response or toxicity. Journal of Clinical Pharmacy and Therapeutics, 39(5), 555-560.
DOI Scopus6 WoS5 Europe PMC4
2014 Wiese, M., Alotaibi, N., O'Doherty, C., Sorich, M., Suppiah, V., Cleland, L., & Proudman, S. (2014). Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis. Pharmacogenomics Journal, 14(4), 350-355.
DOI Scopus24 WoS21 Europe PMC21
2014 Mahurkar, S., Suppiah, V., & O'Doherty, C. (2014). Corrigendum to "Pharmacogenomics of interferon beta and glatiramer acetate response: A review of the literature" [Autoimmun. Rev. 13 (2013) 178-186] doi: 10.1016/j.autrev.2013.10.012. Autoimmunity Reviews, 13(12), 1243.
DOI Scopus2 WoS1
2014 OConnor, K. S., Ahlenstiel, G., Suppiah, V., Schibeci, S., Ong, A., Leung, R., . . . Booth, D. R. (2014). IFNL3 mediates interaction between innate immune cells: implications for hepatitis C virus pathogenesis. Innate Immunity, 20(6), 598-605.
DOI Scopus15 WoS15 Europe PMC14
2014 Wiese, M. D., Suppiah, V., & O'Doherty, C. (2014). Metabolic and safety issues for multiple sclerosis pharmacotherapy: opportunities for personalised medicine. Expert opinion on drug metabolism & toxicology, 10(8), 1145-1159.
DOI Scopus3 WoS2 Europe PMC1
2014 O'connor, K. S., Parnell, G., Patrick, E., Ahlenstiel, G., Suppiah, V., Van Der Poorten, D., . . . Booth, D. R. (2014). Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent. Genes and Immunity, 15(2), 88-94.
DOI Scopus20 WoS20 Europe PMC19
2014 Flynn, J. K., Sacks-Davis, R., Higgs, P., Aitken, C., Moneer, S., Suppiah, V., . . . Hellard, M. (2014). Detection of HCV-specific IFN-γ responses in HCV antibody and HCV RNA negative injecting drug users. Hepatitis Monthly, 14(1), e14678-1-e14678-14.
DOI Scopus6 WoS5 Europe PMC5
2014 Mahurkar, S., Suppiah, V., & O'Doherty, C. (2014). Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature. Autoimmunity reviews, 13(12), 178-186.
DOI Scopus55 WoS54 Europe PMC43
2013 Sacks-Davis, R., Aitken, C. K., Higgs, P., Spelman, T., Pedrana, A. E., Bowden, S., . . . Hellard, M. (2013). High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort study. PLoS ONE, 8(11), e80216-1-e80216-12.
DOI Scopus52 WoS50 Europe PMC49
2013 Suppiah, V., Armstrong, N. J., O'Connor, K. S., Berg, T., Weltman, M., Abate, M. L., . . . Ahlenstiel, G. (2013). CCR5-Δ32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection. Genes and Immunity, 14(5), 286-290.
DOI Scopus5 WoS4 Europe PMC5
2013 Mahurkar, S., Moldovan, M., Suppiah, V., & O'Doherty, C. (2013). Identification of shared genes and pathways: a comparative study of multiple sclerosis susceptibility, severity and response to interferon beta treatment. PLoS one, 8(2, article no. e57655), 1-9.
DOI Scopus19 WoS20 Europe PMC18
2012 Patin, E., Kutalik, Z., Guergnon, J., Bibert, S., Nalpas, B., Jouanguy, E., . . . Abel, L. (2012). Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology, 143(5), 1244-1252.e12.
DOI Scopus141 WoS126 Europe PMC106
2012 Fischer, J., Böhm, S., Scholz, M., Müller, T., Witt, H., George, J., . . . Berg, T. (2012). Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology, 55(6), 1700-1710.
DOI Scopus75 WoS69 Europe PMC62
2011 Suppiah, V., Gaudieri, S., Armstrong, N. J., O'Connor, K. S., & Booth, D. R. (2011). IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European cohort: A cross-sectional study. PLoS Medicine, 8(9), 1-8.
DOI Scopus106 WoS105 Europe PMC88
2011 Smith, K. R., Suppiah, V., O'Connor, K., Berg, T., Weltman, M., Abate, M. L., . . . Barrie, H. (2011). Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome medicine, 3(57), 1-13.
DOI Scopus72 WoS63 Europe PMC50
2010 Grebely, J., Petoumenos, K., Hellard, M., Matthews, G., Suppiah, V., Applegate, T., . . . Dore, G. (2010). Potential role for Interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Journal of gastroenterology and hepatology, 52(4), 1216-1224.
DOI Scopus156 WoS131 Europe PMC118
2009 Suppiah, V., Moldovan, M., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M. L., . . . George, J. (2009). IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nature genetics, 41(10), 1100-1104.
DOI Scopus1754 WoS1584 Europe PMC1400
2007 Quirico-Santos, T., Suppiah, V., Heggarty, S., Caetano, R., Alves-Leon, S., & Vandenbroeck, K. (2007). Study of polymorphisms in the interleukin-4 and IL-4 receptor genes in a population of Brazilian patients with multiple sclerosis. Arquivos De Neuro Psiquiatria, 65(1), 15-19.
DOI Scopus12 WoS11 Europe PMC7
2007 Heggarty, S., Suppiah, V., Silversides, J., King, C. E., Droogan, A., McDonnell, G., . . . Vandenbroeck, K. (2007). CTLA4 gene polymorphisms and multiple sclerosis in Northern Ireland. Journal of Neuroimmunology, 187(1-2), 187-191.
DOI Scopus26 WoS23 Europe PMC20
2006 Suppiah, V., Rooney, M., & Vandenbroeck, K. (2006). Polymorphisms in the interleukin-4 and IL-4 receptor genes modify risk for chronic inflammatory arthropathies in women. Experimental and Molecular Pathology, 81(3), 239-244.
DOI Scopus11 WoS10 Europe PMC9
2006 Suppiah, V., King, C. E., Heggarty, S., Patterson, C., Rooney, M., & Vadenbroeck, K. (2006). The CTLA4 + 49A/G and CT60 polymorphisms and chronic inflammatory arthropathies in Northern Ireland. Experimental and Molecular Pathology, 80(2), 141-146.
DOI Scopus36 WoS33 Europe PMC29
2005 Suppiah, V., Alloza, I., Heggarty, S., Goris, A., Dubois, B., Carton, H., & Vandenbroeck, K. (2005). The CTLA4 +49 A/G*G-CT60*G haplotype is associated with susceptibility to multiple sclerosis in Flanders. Journal of Neuroimmunology, 164(1-2), 148-153.
DOI Scopus42 WoS38 Europe PMC33
2005 Suppiah, V., Goris, A., Alloza, I., Heggarty, S., Dubois, B., Carton, H., . . . Vandenbroeck, K. (2005). Polymorphisms in the interleukin-4 and IL-4 receptor genes and multiple sclerosis: A study in Spanish-Basque, Northern Irish and Belgian populations. International Journal of Immunogenetics, 32(6), 383-388.
DOI Scopus33 WoS27 Europe PMC24

Year Citation
2015 Matti, N., Khoo, S. N., Wiese, M., King, C., & Suppiah, V. (2015). Teaching of Pharmacogenomics in Australian Pharmacy Schools. In PUBLIC HEALTH GENOMICS Vol. 18 (pp. 47-48). KARGER.
WoS2
2013 Eslam, M., Leung, R., Berg, T., Irving, W. L., Mangia, A., Sheridan, D., . . . Ahlenstiel, G. (2013). Association of <i>IFNL3</i> polymorphisms with fibrosis progression in viral and non-viral chronic liver disease. In JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY Vol. 28 (pp. 67). WILEY-BLACKWELL.
2012 Patin, E., Kutalik, Z., Guergnon, J., Bibert, S., Nalpas, B., Jouanguy, E., . . . Bochud, P. -Y. (2012). GENOME-WIDE ASSOCIATION STUDY IDENTIFIES VARIANTS ASSOCIATED WITH LIVER FIBROSIS PROGRESSION IN HCV-INFECTED PATIENTS. In JOURNAL OF HEPATOLOGY Vol. 56 (pp. S551). Barcelona, SPAIN: ELSEVIER SCIENCE BV.
DOI WoS1
2011 Grebely, J., Matthews, G. V., Hellard, M., Suppiah, V., Petoumenos, K., Applegate, T., . . . Dore, G. J. (2011). IL28B GENOTYPE HAS VARIABLE INFLUENCE ON EARLY VIRAL KINETICS, BUT NO INFLUENCE ON SUSTAINED VIROLOGICAL RESPONSE DURING TREATMENT FOR RECENT HEPATITIS C VIRUS INFECTION. In JOURNAL OF HEPATOLOGY Vol. 54 (pp. S524). Berlin, GERMANY: ELSEVIER.
DOI WoS1
2011 Feld, J. J., Grebely, J., Applegate, T., Matthews, G. V., Hellard, M., Suppiah, V., . . . Dore, G. J. (2011). IP-10 IS ASSOCIATED WITH EARLY VIRAL KINETICS, BUT NOT SUSTAINED VIROLOGICAL RESPONSE DURING TREATMENT FOR RECENT HEPATITIS C VIRUS INFECTION. In JOURNAL OF HEPATOLOGY Vol. 54 (pp. S455). Berlin, GERMANY: ELSEVIER.
DOI
2011 Sacks-Davis, R., Aitken, C., Higgs, P., Moneer, S., Flynn, J., Suppiah, V., . . . Hellard, M. (2011). HEPATITIS C VIRUS-SPECIFIC CELLULAR IMMUNITY DOES NOT PROTECT AGAINST FUTURE HCV INFECTION IN ANTI-HCV NEGATIVE INJECTING DRUG USERS. In JOURNAL OF HEPATOLOGY Vol. 54 (pp. S326). Berlin, GERMANY: ELSEVIER.
DOI
2011 Sacks-Davis, R., Aitken, C., Higgs, P., Spelman, T., Pedrana, A., Bowden, S., . . . Hellard, M. (2011). HEPATITIS C CLEARANCE AND REINFECTION IN A COHORT OF PEOPLE WHO INJECT DRUGS: BEHAVIOURAL AND GENETIC CORRELATES. In HEPATOLOGY Vol. 54 (pp. 1180A). San Francisco, CA: WILEY-BLACKWELL.
2011 Fischer, J., Boehm, S., Mueller, T., van Boemmel, F., Fueloep, B., Migaud, P., . . . Berg, T. (2011). COMBINED EFFECTS OF IL28B GENETIC VARIANTS (SNPS RS12979860 AND RS8099917) ON OUTCOME OF STANDARD HCV-TREATMENT. In HEPATOLOGY Vol. 54 (pp. 829A). San Francisco, CA: WILEY-BLACKWELL.
2011 Applegate, T., Gaudieri, S., Pham, S., White, P., Grebely, J., Hellard, M., . . . Matthews, G. V. (2011). Impact of host and viral characteristics on treatment outcome within hepatitis C transmission clusters in HIV-positive individuals with recently acquired HCV. In ANTIVIRAL THERAPY Vol. 16 (pp. A87). Los Cabos, MEXICO: INT MEDICAL PRESS LTD.
2010 Smith, K. R., Suppiah, V., Stewart, G., Booth, D. R., George, J., & Bahlo, M. (2010). Refining Genetic Associations with Hepatitis C Treatment Response Using Massively Parallel Sequencing of Pooled DNA Following a Genome Wide Association Study. In GENETIC EPIDEMIOLOGY Vol. 34 (pp. 926). Boston, MA: WILEY-BLACKWELL.
2009 Moldovan, M., Suppiah, V., Booth, D., George, J., & Bahlo, M. (2009). Prediction Modeling in the Context of Pharmacogenomic Genome-wide Association Study: Identifying Non-responders to PegINF-alpha/ribavirin Treatment Among Chronic Genotype 1 Hepatitis C Virus Infected Individuals. In GENETIC EPIDEMIOLOGY Vol. 33 (pp. 808). Honolulu, HI: WILEY-LISS.
2005 Suppiah, V., Heggarty, S., Droogan, A., McDonnell, G., Hawkins, S., Goris, A., . . . Vandenbroeck, K. (2005). Interlukin-4 (IL-4) and IL-4 receptor (IL-4R) polymorphisms: Influence on clinical course of multiple sclerosis (MS). In JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY Vol. 76 (pp. 1320). Queen Univ Belfast, Belfast, IRELAND: B M J PUBLISHING GROUP.
2005 Vandenbroeck, K., Alloza, I., Heggarty, S., Goris, A., Suppiah, V., & Rooney, M. (2005). High-resolution identification of an interferon-gamma gene haplotype associated with rheumatoid arthritis in male but not female patients.. In ARTHRITIS AND RHEUMATISM Vol. 52 (pp. S148). San Diego, CA: WILEY-BLACKWELL.
2005 Suppiah, V., Heggarty, S., O'Doherty, C., Rooney, M., & Vandenbroeck, K. (2005). CTLA-4 gene polymorphisms in chronic inflammatory arthropathies.. In ARTHRITIS AND RHEUMATISM Vol. 52 (pp. S147). San Diego, CA: WILEY-BLACKWELL.
2005 Suppiah, V., Heggarty, S., Alloza, I., Patterson, C., Rooney, M., & Vandenbroeck, K. (2005). Polymorphisms in the interleukin-4 and interleukin-4 receptor genes are associated with chronic inflammatory arthropathies. In ARTHRITIS AND RHEUMATISM Vol. 52 (pp. S147). San Diego, CA: WILEY-BLACKWELL.
- Lloyd, R., Petito, E., Suppiah, V., Hall, C., Williams, M., & Hotham, E. (n.d.). An audit of medications across two sites of an aged care organization in South Australia. In RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY Vol. 12 (pp. E38). ELSEVIER SCIENCE INC.

Year Citation
2019 Aburas, D., Prosser, A., Hendrix, I., Suppiah, V., & Johnson, J. (2019). THE PAIN OF OPIOIDS ON DISCHARGE: EXPLORING PRESCRIBING PATTERNS AND HANDOVER TO PRIMARY CARE FOR GERIATRIC PATIENTS. Poster session presented at the meeting of RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY. ELSEVIER SCIENCE INC.
2019 Bony, H., Searle, K., Zuher, H., Suppiah, V., & Hotham, E. (2019). DETERMINATION OF THE KNOWLEDGE BASE OF COMMUNITY PHARMACY CLIENTS IN RELATION TO MENTAL HEALTH CONDITIONS AND MENTAL HEALTH SUPPORT SERVICES.. Poster session presented at the meeting of RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY. ELSEVIER SCIENCE INC.
2019 Baker, M. L., Leiblich, H., Paulose, M. A., Schiller, C., Pegoli, M., Panagopoulos, L., . . . Suppiah, V. (2019). AUDIT ON THE INCIDENCE & MANAGEMENT OF DRUG-RELATED HOSPITAL ADMISSIONS FOR DRUG-INDUCED GASTRO-INTESTINAL BLEEDING.. Poster session presented at the meeting of RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY. ELSEVIER SCIENCE INC.
2019 Suppiah, V., Bony, H., Corre, L. J., & Hotham, E. (2019). PSYCHOTROPIC MEDICATIONS USE IN SOUTH AUSTRALIA: COMPARISON OF RESIDENTIAL AGED CARE RESIDENTS WITH COMMUNITY DWELLERS.. Poster session presented at the meeting of RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY. ELSEVIER SCIENCE INC.
2013 Wiese, M., Alotabi, N., O'Doherty, C., Sorich, M., Suppiah, V., Cleland, L., & Proudman, S. (2013). Variability in genes that encode N-acetyl transferase 2 and ABCG2 and disease outcomes in early rheumatoid arthritis. Poster session presented at the meeting of Australian Rheumatology Association in conjunction with the Rheumatology Health Professionals Association 54th Annual Scientific Meeting, as published in Internal Medicine Journal. Perth, W.A.: Wiley-Blackwell.
DOI

Year Citation
2024 Stacey, D., Suppiah, V., Benyamin, B., Lee, H., & Hyppönen, E. (2024). In-silico functional analyses identify<i>TMPRSS15</i>-mediated intestinal absorption of lithium as a modulator of lithium response in bipolar disorder.
DOI

  • Prevalence of psychotropic polypharmacy and its chronic health implications in South Australian prisons, South Australian Prison Health Service, 02/02/2024 - 31/12/2027

  • Minimising Adverse drug Reactions and Verifying Economic Legitimacy – Pharmacogenetic Implementation in Children (MARVEL-PIC), MRFF - Genomics Health Futures Mission, 01/01/2023 - 31/12/2026

  • Evaluation of the Dementia Support Pharmacist in Regional South Australia Program, Pharmaceutical Society of Australia - South Australia Branch, 02/06/2025 - 30/11/2025

  • The Pharmacy Guild of Australia Scholarship, The Pharmacy Guild of Australia, 01/04/2022 - 31/12/2024

  • Evaluation of Hand'n'Hand Services, HAND N HAND SERVICES LTD, 01/06/2024 - 20/12/2024

  • Optimization and validation of assay of French protocol for phenotyping patient samples for treatment optimization, Pari-Passou Medical Consultancy, 03/08/2020 - 31/12/2020

  • Cost effectiveness analysis of NPS MedicineWise app in the management of heart failure patients, DISER-Innovation Connections Grant, 06/05/2019 - 04/05/2020

Courses I teach

  • PHAR 3022 Pharmacotherapeutics Theory 2 (2025)
  • PHAR 3024 Dosage Form Design 3 (2025)
  • PHAR 3022 Pharmacotherapeutics Theory 2 (2024)
  • PHAR 3024 Dosage Form Design 3 (2024)

Programs I'm associated with

  • IHPC - Bachelor of Pharmacy (Honours)
  • IBPA - Bachelor of Pharmaceutical Science
  • IHPP - Bachelor of Pharmaceutical Science, Bachelor of Pharmacy (Honours)

Connect With Me

External Profiles

Other Links